Kyntra Bio Inc (KYNB) Stock Price, Quote & News

Company Profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 978 1200

Fax: 415 978 1902

Website: www.kyntrabio.com

Address:

350 Bay Street, Suite 100 #6009, San Francisco, United States

ARKADIY_PAROVOZOV Jul. 3 at 8:27 AM

$KYNB New preprint on bioRxiv examines biological mechanisms related to the HIF pathway (Roxadustat class). Early-stage research. https://www.biorxiv.org/content/10.64898/2026.06.29.735161v1

0 · Reply

ARKADIY_PAROVOZOV Jul. 3 at 8:27 AM

$KYNB Article on Chinese medical platform discusses Roxadustat for anemia management. Additional supporting regional information. https://www.coagulation-factor-ii.com/index.php?g=Wap&m=Article&a=detail&id=376

0 · Reply

ARKADIY_PAROVOZOV Jul. 3 at 8:27 AM

$KYNB New study in Renal Failure evaluates the use of Roxadustat in patients with chronic kidney disease anemia. Supportive clinical data. https://www.tandfonline.com/doi/pdf/10.1080/0886022X.2026.2667684

0 · Reply

MaxMiamiFl Jul. 2 at 5:51 PM

$KYNB Slow and steady wins it. ........LETS GO! MERGE/SELL/DO SOMETHING!

0 · Reply

ARKADIY_PAROVOZOV Jul. 2 at 10:43 AM

$KYNB Just found this May 2026 meta-analysis on PubMed: Roxadustat significantly improves hemoglobin levels and reduces transfusion dependence in lower-risk MDS patients. Supportive data for Kyntra’s upcoming Phase 3 program. https://pubmed.ncbi.nlm.nih.gov/42185813/

0 · Reply

MaxMiamiFl Jul. 1 at 4:28 PM

$KYNB A total joke: Mkt Cap $30.56M ...........should be $100 M

0 · Reply

ARKADIY_PAROVOZOV Jul. 1 at 8:12 AM

$KYNB Roxadustat continues to show broader HIF-1α-driven potential beyond anemia, with new data suggesting relevance in inflammatory and transplant-related settings. https://www.sciencedirect.com/science/article/pii/S2590059526002190

0 · Reply

MaxMiamiFl Jun. 30 at 6:29 PM

$KYNB LETS GO!!!.......this is nothing. 7.64/25= 0.30....cents.......needs to be at a $1 or $2

0 · Reply

ARKADIY_PAROVOZOV Jun. 30 at 9:34 AM

$KYNB STTT journal post highlights multicenter trial results on Sirolimus + Roxadustat combination for pure red cell aplasia. Expanding possible applications of Roxadustat. https://www.facebook.com/sigtrans.sttt/posts/sirolimus-roxadustat-therapy-for-pure-red-cell-aplasia-findings-in-sttta-multice/122212878434532916/

0 · Reply

ARKADIY_PAROVOZOV Jun. 30 at 9:34 AM

$KYNB New study shows that Roxadustat (via HIF-1α stabilization) may reduce gastrointestinal graft-versus-host disease (GVHD) in models of bone marrow transplantation. Interesting potential in transplant medicine. https://www.researchgate.net/publication/408157188_Stabilization_of_HIF-1a_using_the_prolyl_hydroxylase_inhibitor_roxadustat_reduces_gastrointestinal_graft-versus-host_disease

0 · Reply

Kyntra Bio Transcript: AGM 2026

2026-06-11T20:20:00.000Z - 23 days ago

Kyntra Bio to present additional MATTERHORN trial data at EHA

Jun 11, 2026, 4:05 PM EDT - 23 days ago

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

2026-06-09T11:16:47.000Z - 25 days ago

Kyntra Bio initiated with a Buy at Rodman & Renshaw

May 11, 2026, 5:00 PM EDT - 7 weeks ago

Kyntra Bio Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

Kyntra Bio Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

Kyntra Bio Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 7 weeks ago

Kyntra Bio Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 7 weeks ago

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 4:05 PM EDT - 2 months ago

Kyntra Bio to Report First Quarter 2026 Financial Results

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Kyntra Bio Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Kyntra Bio Proxy statement: Proxy filing

Apr 13, 2026, 1:30 PM EDT - 2 months ago

Kyntra Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 4:05 PM EDT - 3 months ago

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

Mar 16, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Earnings Call Transcript: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Annual report: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Earnings release: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Slides: Q4 2025

Mar 16, 2026, 4:02 PM EDT - 3 months ago

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 11, 2026, 2:20 PM EDT - 4 months ago

Kyntra Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 7:00 AM EDT - 4 months ago

Kyntra Bio Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 2:40 PM EST - 4 months ago

Kyntra Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-23T22:16:08.000Z - 4 months ago

Kyntra Bio announces positive data from Phase 1b/2 study of FG-3246

Feb 23, 2026, 5:10 PM EST - 4 months ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

Feb 17, 2026, 4:05 PM EST - 4 months ago

Kyntra Bio to Participate in Upcoming Investor Conferences

Jan 7, 2026, 7:30 AM EST - 6 months ago

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Earnings release: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Slides: Q3 2025

Nov 3, 2025, 4:02 PM EST - 8 months ago

FibroGen to Report Third Quarter 2025 Financial Results

Sep 24, 2025, 7:00 AM EDT - 10 months ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Sep 9, 2025, 12:00 PM EDT - 10 months ago

Kyntra Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:02 PM EDT - 11 months ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 7:00 AM EDT - 11 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 11, 2025, 5:00 PM EDT - 11 months ago

Kyntra Bio Earnings Call Transcript: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 11 months ago

Kyntra Bio Quarterly report: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 11 months ago

Kyntra Bio Earnings release: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 11 months ago

Kyntra Bio Slides: Q2 2025

Aug 11, 2025, 4:02 PM EDT - 11 months ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 4:02 PM EDT - 11 months ago

FibroGen to Report Second Quarter 2025 Financial Results

Jun 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 9, 2025, 4:02 PM EDT - 1 year ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q1 2025

May 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:24 AM EDT - 1 year ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 5, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Report First Quarter 2025 Financial Results

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 2, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Annual report: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q4 2024

Mar 17, 2025, 4:05 PM EDT - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Transcript: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Press release: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Slides: Status Update

Feb 20, 2025, 6:40 AM EST - 1 year ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

Feb 20, 2025, 6:30 AM EST - 1 year ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Slides: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

Sep 10, 2024, 3:00 PM EDT - 1 year ago

Kyntra Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q2 2024

Jul 30, 2024, 4:07 PM EDT - 2 years ago

FibroGen to Report Second Quarter 2024 Financial Results

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Registration statement: Registration Filing

Jun 10, 2024, 10:00 AM EDT - 2 years ago

Kyntra Bio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 4:05 PM EDT - 2 years ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

May 23, 2024, 5:05 PM EDT - 2 years ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 20, 2024, 1:30 PM EDT - 2 years ago

Kyntra Bio Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Participate in Upcoming Investor Conferences

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q1 2024

May 6, 2024, 4:02 PM EDT - 2 years ago

FibroGen Reports First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Report First Quarter 2024 Financial Results

Apr 24, 2024, 4:02 PM EDT - 2 years ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 3:00 PM EDT - 2 years ago

Kyntra Bio Slides: 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 5:46 PM EDT - 2 years ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Mar 26, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 11, 2024, 7:00 AM EDT - 2 years ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q4 2023

Feb 26, 2024, 4:18 PM EST - 2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

Feb 26, 2024, 4:06 PM EST - 2 years ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 20, 2024, 7:00 AM EST - 2 years ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 10:30 AM EST - 2 years ago

Kyntra Bio Transcript: Study Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Jan 25, 2024, 7:00 AM EST - 2 years ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 10, 2024, 3:00 PM EST - 2 years ago

Kyntra Bio Slides: Corporate Presentation

Dec 9, 2023, 5:02 PM EST - 2 years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Quarterly report: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q3 2023

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 2 years ago

FibroGen to Report Third Quarter 2023 Financial Results

ARKADIY_PAROVOZOV Jul. 3 at 8:27 AM

$KYNB New preprint on bioRxiv examines biological mechanisms related to the HIF pathway (Roxadustat class). Early-stage research. https://www.biorxiv.org/content/10.64898/2026.06.29.735161v1

0 · Reply

ARKADIY_PAROVOZOV Jul. 3 at 8:27 AM

0 · Reply

ARKADIY_PAROVOZOV Jul. 3 at 8:27 AM

0 · Reply

MaxMiamiFl Jul. 2 at 5:51 PM

$KYNB Slow and steady wins it. ........LETS GO! MERGE/SELL/DO SOMETHING!

0 · Reply

ARKADIY_PAROVOZOV Jul. 2 at 10:43 AM

0 · Reply

MaxMiamiFl Jul. 1 at 4:28 PM

$KYNB A total joke: Mkt Cap $30.56M ...........should be $100 M

0 · Reply

ARKADIY_PAROVOZOV Jul. 1 at 8:12 AM

0 · Reply

MaxMiamiFl Jun. 30 at 6:29 PM

$KYNB LETS GO!!!.......this is nothing. 7.64/25= 0.30....cents.......needs to be at a $1 or $2

0 · Reply

ARKADIY_PAROVOZOV Jun. 30 at 9:34 AM

0 · Reply

ARKADIY_PAROVOZOV Jun. 30 at 9:34 AM

0 · Reply

MaxMiamiFl Jun. 29 at 7:54 PM

$KYNB LETS MAKE IT TO $12.50 AND ABOVE

0 · Reply

ARKADIY_PAROVOZOV Jun. 28 at 8:05 AM

$KYNB This Kidney International Reports abstract suggests that long-term roxadustat treatment in hemodialysis patients maintained hematopoietic efficacy while dose and cost gradually declined over 100 weeks, with no severe adverse events reported. https://www.kireports.org/article/S2468-0249(26)01078-8/pdf

0 · Reply

ARKADIY_PAROVOZOV Jun. 27 at 11:46 AM

$KYNB New publication in Scientific Reports (Nature) explores the mechanisms and potential of Roxadustat in anemia treatment. Additional supporting scientific data for the drug. https://www.nature.com/articles/s41598-026-57571-6

0 · Reply

ARKADIY_PAROVOZOV Jun. 27 at 11:44 AM

$KYNB Recent work suggests that sirolimus + roxadustat may synergistically support erythropoiesis and immunosuppression in pure red cell aplasia, adding another layer to the roxadustat story. https://x.com/sigtrans_sttt/status/2070479689294975013

0 · Reply

MaxMiamiFl Jun. 26 at 1:40 PM

$KYNB dont know where 7.48 comes from.............it is below $7

0 · Reply

ARKADIY_PAROVOZOV Jun. 26 at 1:32 PM

$KYNB Recent paper in Experimental Hematology discusses the effects of HIF-PH inhibitors on erythropoiesis. Good supporting research for the drug class. https://www.sciencedirect.com/science/article/pii/S0011393X26000184

1 · Reply

ARKADIY_PAROVOZOV Jun. 26 at 1:32 PM

$KYNB New study in eLife explores the molecular regulation of erythropoiesis through the HIF pathway, with references to Roxadustat. Interesting mechanistic insights. https://elifesciences.org/articles/108128

0 · Reply

ARKADIY_PAROVOZOV Jun. 26 at 1:31 PM

$KYNB Pharmacists are playing a key role in evolving anemia management in CKD, with Roxadustat highlighted as a modern treatment option. https://www.facebook.com/APhAPharmacists/posts/anemia-management-in-ckd-is-evolving-and-pharmacists-are-often-the-ones-translat/1456832159820211/

0 · Reply

ARKADIY_PAROVOZOV Jun. 26 at 11:51 AM

$KYNB yesterday there was an unusual volume of trading on the stock, it was very interesting

1 · Reply

ARKADIY_PAROVOZOV Jun. 23 at 8:53 AM

$KYNB New review in Frontiers in Bioengineering and Biotechnology explores the molecular mechanisms and clinical potential of HIF-PH inhibitors, including Roxadustat, in anemia treatment. Good supporting scientific background. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1708887/pdf

1 · Reply

ARKADIY_PAROVOZOV Jun. 23 at 8:52 AM

$KYNB New systematic review and meta-analysis published in Journal of Clinical Medicine confirms that Roxadustat significantly improves hemoglobin levels in CKD patients compared to placebo. Good supporting data for the drug. https://www.mdpi.com/2571-6980/7/3/18

0 · Reply

MaxMiamiFl Jun. 22 at 3:18 PM

$KYNB just for the hell of it 😂

0 · Reply

Market Cap	30.89M
Revenue (ttm)	6.44M
Net Income (ttm)	183.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	2,848.60%
Debt to Equity Ratio	0.00

Volume	4,900
Avg Vol	19,220
Day's Range	N/A - N/A
Shares Out	4.05M
Stochastic %K	85%
Beta	0.96
Analysts	Sell
Price Target	$36.50